Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1354

Sort by

Sort Order Select

Journal Articles

Unravelling the apoptotic machinery in CMML

Justin Loke, Peter N. Cockerill

Blood (2021) 137 (24): 3321–3322.

https://doi.org/10.1182/blood.2021011363

Published: 2021

Journal Articles

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

Blood (2021) 137 (24): 3390–3402.

https://doi.org/10.1182/blood.2020008729

Published: 2021

Includes: Supplemental data

Journal Articles

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1

Roger Belizaire, Sebastian H. J. Koochaki, Namrata D. Udeshi, Alexis Vedder, Lei Sun, Tanya Svinkina, Christina Hartigan, Marie McConkey, Veronica Kovalcik, Amanuel Bizuayehu, Caroline Stanclift, Monica Schenone, Steven A. Carr, Eric Padron, Benjamin L. Ebert

Blood (2021) 137 (16): 2209–2220.

https://doi.org/10.1182/blood.2020006528

Published: 2021

Includes: Supplemental data

Journal Articles

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Blood (2021) 137 (10): 1377–1391.

https://doi.org/10.1182/blood.2020007897

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia

Blood (2020) 136 (7): 909–913.

https://doi.org/10.1182/blood.2019004352

Published: 2020

Includes: Supplemental data

Journal Articles

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia-Manero, Elizabeth A. Griffiths, David P. Steensma, Gail J. Roboz, Richard Wells, James McCloskey, II, Olatoyosi Odenike, Amy E. DeZern, Karen Yee, Lambert Busque, Casey O’Connell, Laura C. Michaelis, Joseph Brandwein, Hagop Kantarjian, Aram Oganesian, Mohammad Azab, Michael R. Savona

Blood (2020) 136 (6): 674–683.

https://doi.org/10.1182/blood.2019004143

Published: 2020

Journal Articles

Low Serum Albumin Level Predicts the Risk of Azacitidine Early Discontinuation in MDS, CMML and 20-30% AML Patients- Results from the Polaza, the Retrospective Study of the Polish Adult Leukemia Group

Blood (2019) 134 (Supplement_1): 5421.

https://doi.org/10.1182/blood-2019-125632

Published: 2019

Journal Articles

Anabolic Steroids in Myelodysplastic Syndromes: A Systematic Review

Alejandro Garcia-Horton, MDFRCPC, Yashoda Valliere, Alejandro Lazo-Langner, MD MSc

Blood (2019) 134 (Supplement_1): 5425.

https://doi.org/10.1182/blood-2019-126806

Published: 2019

Journal Articles

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Jamie Koprivnikar, MD, James K McCloskey, MD, Rena Feinman, PhD, Robert Korngold, PhD, Michele L. Donato, MD, Scott D. Rowley, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD

Blood (2019) 134 (Supplement_1): 5618.

https://doi.org/10.1182/blood-2019-132025

Published: 2019

Journal Articles

Generation of a New Prognostic Index for Chronic Myelomonocytic Leukemia (CMML) Based on Peripheral Blood Assessment

David Roman, MD, Leonor Arenillas, MD PhD, Ivonne Parraga, Fellow, Lourdes Florensa, MD PhD, Sara Montesdeoca, MD, Marta Salido, PhD, Puiggros Anna, Blanca Espinet, PhD, Lluís Colomo, MD PhD, Marcio Andrade, MD PhD, Brayan Merchan, MD MSc, Ana Ferrer, MD PhD, Xavier Calvo, MD PhD

Blood (2019) 134 (Supplement_1): 4262.

https://doi.org/10.1182/blood-2019-128768

Published: 2019

Journal Articles

In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial

Blood (2019) 134 (Supplement_1): 4247.

https://doi.org/10.1182/blood-2019-123921

Published: 2019

Journal Articles

Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia

Moritz Binder, MDMPH, Ryan Carr, MD PhD, Nathalie Droin, PhD, Abhishek A Mangaonkar, MBBS, Giacomo Coltro, MD, Luciana L Almada, PhD, David Marks, PhD, Kurt Berger, Terra Lasho, PhD, Naseema Gangat, MBBS, Christopher Pin, PhD, Martin Fernandez-Zapico, MD, Eric Solary, MD PhD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 4232.

https://doi.org/10.1182/blood-2019-122187

Published: 2019

Journal Articles

A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML)

Mrinal M Patnaik, MDMBBS, David A Sallman, MD, Abhishek A Mangaonkar, MBBS, Rachel Heuer, Jeffery Hirvela, Darci Zblewski, APRN, C-NP, Aref Al-Kali, MD, Deanna Kanne, Rahil Ismail, Rami S. Komrokji, MD, Adrian Lo, Maria E Balasis, Cameron Durrant, Dale Chappell, Omar Ahmed, Alan F. List, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 4234.

https://doi.org/10.1182/blood-2019-131181

Published: 2019

Journal Articles

Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML) and Chronic Myelomonocytic Leukemia (CMML) Show Similar Clinical, Morphological, Immunophenotypic and Molecular Features

Xavier Calvo, MD PhD, Nieves Garcia-Gisbert, MSc, Ivonne Parraga, Fellow, Lourdes Florensa, MD PhD, Sara Montesdeoca, MD, Concepción Fernández, Marta Salido, PhD, Anna Puiggros, PhD, Blanca Espinet, PhD, Beatriz Bellosillo, PhD, Lluís Colomo, MD PhD, David Roman, MD, Marcio Andrade, MD PhD, Brayan Merchan, MD MSc, Ana Ferrer, MD PhD, Leonor Arenillas, MD PhD

Blood (2019) 134 (Supplement_1): 4266.

https://doi.org/10.1182/blood-2019-130445

Published: 2019

Journal Articles

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Guillermo Garcia-Manero, MD, Shyamala C. Navada, MD, Pierre Fenaux, MD PhD, Patrick S. Zbyszewski, MBA, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4268.

https://doi.org/10.1182/blood-2019-132149

Published: 2019

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Amer M Zeidan, MD, Yasushi Miyazaki, MD PhD, Uwe Platzbecker, Kamel Malek, Julie Niolat, Flavia Kiertsman, Pierre Fenaux, MD PhD

Blood (2019) 134 (Supplement_1): 4259.

https://doi.org/10.1182/blood-2019-127041

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Blood (2019) 134 (Supplement_1): 4220.

https://doi.org/10.1182/blood-2019-128165

Published: 2019

Journal Articles

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Mathias A. Schneeweiss, Greiner Georg, MD PhD, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, MD, Friedrich Wimazal, MD, Corinna Steinhauser, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Harald Esterbauer, MD PhD, Manuela Födinger, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2019) 134 (Supplement_1): 4269.

https://doi.org/10.1182/blood-2019-123390

Published: 2019

Journal Articles

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Kirk Cahill, MD, Anand Ashwin Patel, MD, Hongtao Liu, MD PhD, Sandeep Gurbuxani, MBBS, PhD, Michael Thirman, MD, Satyajit Kosuri, MD, Andrew S. Artz, MD, Richard A. Larson, MD, Wendy Stock, MD, Jeremy Segal, MD PhD, Olatoyosi Odenike, MD

Blood (2019) 134 (Supplement_1): 4176.

https://doi.org/10.1182/blood-2019-122380

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Unravelling the apoptotic machinery in CMML

Cytokine-like protein 1–induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML

CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Phase 1 study of lenzilumab, a recombinant anti–human GM-CSF antibody, for chronic myelomonocytic leukemia

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Low Serum Albumin Level Predicts the Risk of Azacitidine Early Discontinuation in MDS, CMML and 20-30% AML Patients- Results from the Polaza, the Retrospective Study of the Polish Adult Leukemia Group

Anabolic Steroids in Myelodysplastic Syndromes: A Systematic Review

Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Generation of a New Prognostic Index for Chronic Myelomonocytic Leukemia (CMML) Based on Peripheral Blood Assessment

In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial

Peripheral Blood Cell Sorting Strategies for Transcriptomic Analysis in Chronic Myelomonocytic Leukemia

A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti-Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML)

Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML) and Chronic Myelomonocytic Leukemia (CMML) Show Similar Clinical, Morphological, Immunophenotypic and Molecular Features

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Outcomes of IDH -Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only